I keep getting a strange response when I make an API call to PaLM

[rapidmon17]

Here's my prompt:

{"prompt":{"text":"Using at least 1024 tokens, Tell me about the stock ESPR whose company name is Esperion Therapeutics, Inc.  and list the exactly the following about the stock:\nDetailed Analysis on Business Model and Strategy\nRecent Events\nProduct Launches and products in pipeline\nRegulatory Changes\nMarket Position\nCompetition Analysis\nMergers and Acquisitions\nTechnological Innovations and Disruptions\nStrategic Partnerships and Alliances\nCrisis Events\nIndustry trends and Market Conditions"}}

This is the response I get below:

{
  "filters": [
    {
      "reason": "OTHER"
    }
  ]
}

As you can see it's lacking the candidate in the response. Can someone tell me why this is happening?

[keertk]

Hi @rapidmon17 could you share the exact curl command you're using please? The prompt seems to work for me here:

$ curl https://generativelanguage.googleapis.com/v1beta2/models/text-bison-001:generateText?key=$PALM_API_KEY -H 'Content-Type: application/json' -X POST -d '{"prompt": { "text": "Using at least 1024 tokens, Tell me about the stock ESPR whose company name is Esperion Therapeutics, Inc.  and list the exactly the following about the stock:\nDetailed Analysis on Business Model and Strategy\nRecent Events\nProduct Launches and products in pipeline\nRegulatory Changes\nMarket Position\nCompetition Analysis\nMergers and Acquisitions\nTechnological Innovations and Disruptions\nStrategic Partnerships and Alliances\nCrisis Events\nIndustry trends and Market Conditions" } }'

{
  "candidates": [
    {
      "output": "**Detailed Analysis on Business Model and Strategy**\n\nEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics to treat patients with elevated LDL-C and other cardiometabolic risk factors. The company's lead product candidate, bempedoic acid, is a first-in-class, oral, once-daily ATP-citrate lyase (ACL) inhibitor that is currently in Phase III development for the treatment of patients with hypercholesterolemia. Bempedoic acid is also being evaluated in a Phase IIb study for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).\n\nEsperion's business model is based on the development and commercialization of novel therapeutics to treat patients with elevated LDL-C and other cardiometabolic risk factors. The company's strategy is to focus on developing and commercializing products that address unmet medical needs in large and growing markets. Esperion believes that its lead product candidate, bempedoic acid, has the potential to be a best-in-class treatment for patients with hypercholesterolemia.\n\n**Recent Events**\n\nIn February 2023, Esperion announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for bempedoic acid. The NDA is based on the results of two Phase III clinical trials, which showed that bempedoic acid significantly reduced LDL-C levels in patients with hypercholesterolemia. The FDA is expected to make a decision on the NDA by July 2023.\n\nIn March 2023, Esperion announced that it has entered into a global collaboration and license agreement with Bristol Myers Squibb (BMS) for the development and commercialization of bempedoic acid. Under the terms of the agreement, BMS will be responsible for the development and commercialization of bempedoic acid in all markets outside of the United States. Esperion will receive a $150 million upfront payment from BMS and is eligible to receive up to $1.2 billion in additional milestone payments. Esperion will also receive royalties on sales of bempedoic acid.\n\n**Product Launches and products in pipeline**\n\nEsperion's lead product candidate, bempedoic acid, is currently in Phase III development for the treatment of patients with hypercholesterolemia. The company expects to submit an NDA for bempedoic acid in the United States in the second half of 2023. Esperion is also developing bempedoic acid for the treatment of patients with HoFH. The company expects to initiate a Phase IIb study of bempedoic acid in HoFH in the second half of 2023.\n\nIn addition to bempedoic acid, Esperion has a number of other product candidates in its pipeline. These include:\n\n* ESP001, a small molecule that inhibits PCSK9\n* ESP002, a small molecule that inhibits ANGPTL3\n* ESP003, a small molecule that inhibits MTP\n* ESP004, a small molecule that inhibits LXR\n* ESP005, a small molecule that inhibits FXR\n\n**Regulatory Changes**\n\nIn March 2023, the FDA issued a draft guidance on the development and approval of PCSK9 inhibitors. The guidance provides recommendations on the design of clinical trials for PCSK9 inhibitors and the data that are needed to support approval of these drugs. The guidance is expected to be finalized in the second half of 2023.\n\n**Market Position**\n\nThe global market for cholesterol-lowering drugs is estimated to be worth $20 billion. Esperion's lead product candidate, bempedoic acid, is expected to compete with a number of other cholesterol-lowering drugs, including statins, ezetimibe, and PCSK9 inhibitors.\n\n**Competition Analysis**\n\nEsperion's lead product candidate, bempedoic acid, is expected to compete with a number of other cholesterol-lowering drugs, including statins, ezetimibe, and PCSK9 inhibitors.\n\n* Statins are the most commonly prescribed cholesterol-lowering drugs. They work by inhibiting the enzyme HMG-CoA reductase, which is involved in the synthesis of cholesterol. Statins are effective in reducing LDL-C levels, but they can also cause side effects such as muscle pain, liver damage, and memory loss.\n* Ezetimibe is a cholesterol absorption inhibitor. It works by blocking the absorption of cholesterol from the intestines. Ezetimibe is effective in reducing LDL-C levels, but it does not appear to have the same side effects as statins.\n* PCSK9 inhibitors are a new class of cholesterol-lowering drugs. They work by inhibiting the protein PCSK9, which is involved in the clearance of LDL-C from",
      "safetyRatings": [
        {
          ...
      ],
      "citationMetadata": {
        "citationSources": [
          {
          ...
          }
        ]
      }
    }
  ]
}

[rapidmon17]

Thanks for looking into it. It appears to be working now. I am not sure what that was about. Thanks again!